Drug Prior Authorization Rules Are More Than a Checklist: Understand What Determines Approval, Delays, and Denials

Review drug prior authorization requirements, pharmacy benefit policies, formulary exceptions, quantity limits, clinical documentation, and payer approval procedures….

Table of Contents

A prescription can be clinically appropriate, FDA-approved, and written correctly—and still stop at the pharmacy because the patient’s insurance requires prior authorization.

That is where drug prior authorization becomes more than paperwork. For healthcare providers, medication authorization sits at the intersection of clinical decision-making, pharmacy benefits, medical benefits, formularies, specialty pharmacy, utilization management, coding, and insurance coverage. If any one of those pieces is misunderstood, treatment can be delayed.

Executive Summary of This Guide

1. What is Drug Prior Authorization?

2. First Determine Which Benefit Covers the Drug

3. Some Drugs Can Be Covered Under Either Benefit

4. Start With the Patient’s Current Coverage

5. Identify the Pharmacy Benefit Manager

6. Check the Formulary Before Starting the PA

7. Understand the Difference Between PA, Step Therapy, and Quantity Limits

8. A Formulary Exception is Different From a Standard PA

9. Tier Exceptions Address a Different Problem

10. Use Real-Time Prescription Benefit Information When Available

11. Electronic Prior Authorization Can Begin Inside the EHR

12. Understand the NCPDP SCRIPT Role

13. Medical-Benefit Drugs Follow a Different Electronic Path

14. Build the Drug Authorization From the Prescription Outward

15. Diagnosis is Often the Beginning of the Clinical Review

16. FDA Approval and Insurance Coverage Are Different Questions

17. Previous Treatment History is One of the Most Important PA Elements

18. Contraindicated Should Be Supported

19. Laboratory Requirements Can Be Central to Drug Authorization

20. Specialty Drugs Need More Than a Standard Prescription Workflow

21. Specialty Pharmacy Restrictions Can Affect Access

22. Medical-Benefit Drugs Require Coding Verification

23. Understand HCPCS Units Before Requesting Authorization

24. Loading Doses Can Create Authorization Mismatches

25. Weight-Based Dosing Requires Extra Attention

26. Site-of-Care Programs Can Affect Infusion Drugs

27. Biosimilars Have Changed Specialty Drug Authorization

28. Interchangeability Does Not Mean “Better”

29. Oncology Drug Authorization Needs Disease-Specific Precision

30. Gene and Cell Therapies Require Advanced Authorization Planning

31. Renewal Authorizations Should Begin Before the Current Approval Expires

32. Create a Drug PA Renewal Calendar

33. Pharmacy Rejections Can Reveal the Real Problem

34. Do Not Confuse “Not Covered” With “Prior Authorization Required”

35. Medicare Part D Has Its Own Drug PA Framework

36. Standard and Expedited Part D Requests Are Different

37. Part D Denials Can Be Appealed

38. Medicaid Drug Authorization Follows Another Legal Framework

39. Commercial Drug PA Is Highly Plan-Specific

40. Build a Complete Drug PA Submission Checklist

41. Write the Clinical Rationale Like a Reviewer Will Read It

42. Common Drug PA Denial Reasons

43. Do Root-Cause Analysis Before Resubmitting

44. Peer-to-Peer Review May Be Available for Medical-Benefit Drugs

45. Appeal Letters Should Be Evidence-Driven

46. Manufacturer Assistance Is Not a Substitute for PA

47. Never Promise a Patient That Approval Means Zero Cost

48. Authorization Does Not Guarantee Medical-Claim Payment Either

49. Perform a Pre-Administration Drug Clearance

50. Use a Four-Way Match for Medical-Benefit Drugs

51. Track Drug Authorization Performance

52. Drug Authorization Responsibility Matrix

53. In-House vs. Outsourced Drug Prior Authorization

54. Frequently Asked Questions About Drug Prior Authorization

What is Drug Prior Authorization?

Drug prior authorization is a utilization-management process in which a health plan or pharmacy benefit manager requires certain information before agreeing to cover a prescribed medication. The payer may evaluate questions such as:

  • Does the patient have the condition for which the drug is being prescribed?
  • Is the medication covered under the patient’s plan?
  • Is the requested indication supported?
  • Has the patient tried preferred alternatives?
  • Were those treatments ineffective, contraindicated, or poorly tolerated?
  • Is the dose appropriate?
  • Is the requested quantity within plan limits?
  • Does the patient satisfy age or laboratory requirements?
  • Does the requested treatment meet applicable clinical criteria?
  • Is another medication preferred on the formulary?
  • Does the site of administration satisfy plan requirements?

First Determine Which Benefit Covers the Drug for the Treatment

This should be the first major checkpoint. A drug can be processed through the:

Pharmacy Benefit

These medications are generally dispensed through a:

  • Retail pharmacy
  • Mail-order pharmacy
  • Specialty pharmacy

The pharmacy submits the prescription claim using the patient’s pharmacy benefit.

Medical Benefit

These medications are often administered by a healthcare professional in settings such as:

  • Physician office
  • Infusion center
  • Hospital outpatient department
  • Clinic

They may be billed using HCPCS/J-codes on a medical claim. This distinction changes the authorization workflow.

Pharmacy BenefitMedical Benefit
Prescription/NDC drivenHCPCS/J-code often important
PBM commonly involvedMedical plan/UM program commonly involved
Retail/mail/specialty pharmacyOffice/infusion/HOPD
Formulary central to workflowMedical policy often central
Pharmacy claimMedical claim
ePA commonly uses NCPDP standardsPortal/API/medical PA workflows may apply
Tier/quantity/step therapy commonSite-of-care/dose/units may be central

Never assume that because a medication is a “drug,” it automatically belongs under the pharmacy benefit.

Some Drugs Can Be Covered Under Either Benefit

This is where authorization becomes more complicated. Certain specialty medications may be administered through different channels depending on the payer, product, drug, provider arrangement, and site of care.

For example, the payer may require a specialty medication to be:

Purchased and billed by the provider

or

Dispensed by a specialty pharmacy and delivered for administration

These arrangements are commonly associated with models such as:

Buy-and-Bill

or payer/specialty-pharmacy distribution models sometimes referred to operationally as:

White Bagging

Brown Bagging

or other specialty-drug distribution arrangements.

Do not determine the authorization route from the drug name alone.

Determine:

Member → Benefit → Drug → Administration Method → Site of Care → Payer Requirement

Your Must Start With the Patient’s Current Coverage

Before gathering clinical records, verify the insurance, you need to check:

  • Member name
  • Date of birth
  • Member ID
  • Active coverage
  • Effective date
  • Payer
  • Plan/product
  • Pharmacy benefit
  • Medical benefit
  • PBM when applicable
  • Specialty pharmacy requirements
  • Network requirements

Identify the Pharmacy Benefit Manager

For pharmacy-benefit drugs, knowing the medical insurance company is not always enough in 2027. The plan may use a separate pharmacy benefit manager, or PBM, to administer prescription-drug benefits. The PBM can manage functions such as:

  • Formulary
  • Prior authorization
  • Step therapy
  • Quantity limits
  • Specialty pharmacy
  • Pharmacy network
  • Drug utilization review
  • Prescription claims

A Formulary Exception is Different From a Standard PA

Sometimes the medication is not covered on the plan’s formulary at all. In that situation, the provider may need to request a formulary exception rather than merely demonstrate that ordinary PA criteria have been met.

For Medicare Part D, CMS specifically recognizes formulary exceptions as a type of coverage determination. An exception can be requested for a non-formulary Part D drug or to ask that a utilization-management requirement—such as prior authorization, step therapy, or a quantity limit—be waived. The clinical argument usually needs to explain why covered alternatives are not appropriate. That might involve:

  • Treatment failure
  • Adverse effects
  • Contraindication
  • Drug interaction
  • Clinical ineffectiveness
  • Disease-specific considerations

For Part D formulary exceptions, CMS requires a prescriber supporting statement explaining why the requested medication is medically necessary under the applicable exception criteria.

Tier Exceptions Address a Different Problem

A medication can be covered but placed on a higher-cost tier. For Medicare Part D, a tiering exception can be requested to obtain an eligible non-preferred medication at the cost-sharing level associated with a preferred tier when applicable criteria are satisfied. That means provider staff should distinguish among:

Prior Authorization

Formulary Exception

Tiering Exception

Step-Therapy Exception

Quantity-Limit Exception

Use Real-Time Prescription Benefit Information When Available

Modern prescribing systems increasingly provide patient-specific benefit information before the prescription reaches the pharmacy. Real-time prescription benefit tools can help prescribers identify:

  • Coverage
  • Formulary status
  • Patient-specific cost information
  • Alternatives
  • Utilization-management requirements

Medicare Part D plans have been required to support one or more prescriber real-time benefit tools since 2021. CMS is also moving toward a standardized NCPDP Real-Time Prescription Benefit standard for Part D beginning in 2027. Operationally, this changes the ideal workflow from:

Prescribe → Pharmacy Rejects → Patient Calls Office → Office Discovers PA

to:

Check Benefit → Identify Restriction → Discuss Alternative/PA → Prescribe

Electronic Prior Authorization Can Begin Inside the EHR

Drug authorization does not always require downloading a PDF and faxing it. Electronic prior authorization, or ePA, can allow the prescriber to initiate and respond to pharmacy authorization requests within an electronic prescribing or EHR workflow.

For Medicare Part D, CMS requires Part D sponsors to support electronic prior authorization transactions using the applicable NCPDP SCRIPT standard. CMS adopted NCPDP SCRIPT version 2017071 for this purpose and has established a transition toward version 2023011, which becomes the exclusive Part D e-prescribing standard beginning January 1, 2028.

A simplified ePA workflow is:

Prescription Created

↓

Benefit/Formulary Check

↓

PA Requirement Identified

↓

Electronic PA Questions Returned

↓

Provider Answers Clinical Questions

↓

Documentation Submitted

↓

Payer/PBM Reviews

↓

Decision Returned Electronically

Medical-Benefit Drugs Follow a Different Electronic Path in 2027

Do not confuse Part D pharmacy ePA requirements with authorization for physician-administered drugs under the medical benefit.

CMS’s 2024 interoperability prior-authorization final rule established major API requirements for medical items and services but excluded drugs from those requirements.

In April 2026, CMS proposed expanding electronic prior-authorization requirements to drugs. Among other things, the proposal would bring drugs covered under the medical benefit into FHIR-based PA APIs beginning October 1, 2027 and expand NCPDP-based electronic workflows for specified pharmacy-benefit programs. As of October 2026, those provisions remain proposed rather than final.

So as a provider you should follow current payer workflows rather than assuming all medical-benefit drug PA is already handled through standardized FHIR APIs.

Build the Drug Authorization From the Prescription Outward

Before opening a PA, gather the medication details. A useful medication checklist includes:

FieldWhat to Confirm
DrugExact medication
StrengthPrescribed strength
DoseAmount per administration
RouteOral, IV, SC, IM, etc.
FrequencyHow often
DurationIntended treatment period
QuantityAmount requested
DiagnosisClinical indication
ICD-10-CMApplicable diagnosis code
NDCWhen relevant
HCPCS/J-codeFor medical-benefit drugs
SiteWhere drug will be administered
PrescriberOrdering clinician
PharmacyRequired/selected dispensing pharmacy

Diagnosis is Often the Beginning of the Clinical Review

Drug PA criteria commonly depend on the diagnosis. A medication can be approved for several indications, but payer criteria may differ among those indications.

Documentation should clearly identify:

  • Diagnosis
  • Disease subtype
  • Severity
  • Stage when relevant
  • Duration
  • Symptoms
  • Objective findings

FDA Approval and Insurance Coverage Are Different Questions

FDA approval establishes whether a drug is approved for particular uses based on the agency’s regulatory standards. Insurance coverage is a separate determination. A payer can still apply:

  • Formulary management
  • Prior authorization
  • Step therapy
  • Quantity limits
  • Specialty pharmacy requirements
  • Medical-necessity criteria

Likewise, some medications may be prescribed for off-label uses. Off-label prescribing does not automatically mean a medication is inappropriate, but coverage can depend on the payer, benefit, diagnosis, accepted compendia, clinical evidence, and applicable law.

Previous Treatment History is One of the Most Important PA Elements

Many drug authorization requests fail because the provider writes:

“Patient failed previous therapy.”

That may not be enough.

A stronger record identifies:

DetailExample of Information Needed
MedicationWhat was tried?
DoseAt what dose?
Start dateWhen was it started?
DurationHow long was it used?
ResponseWhat happened?
FailureWhy was it ineffective?
IntoleranceWhat adverse effect occurred?
ContraindicationWhy could it not be used?
DiscontinuationWhen/why was it stopped?

Think:

Drug → Dose → Duration → Outcome

rather than:

Failed drug.

Laboratory Requirements Can Be Central to Drug Authorization

Many medications have authorization criteria involving laboratory values or objective testing. Depending on the therapy, the payer may need information such as:

  • Hemoglobin A1c
  • Lipid values
  • Renal function
  • Liver function
  • CBC
  • Hormone levels
  • Biomarker results
  • Genetic testing
  • Viral testing
  • Pregnancy testing
  • Disease-specific laboratory findings

Specialty Pharmacy Restrictions Can Affect Access

Even when the payer approves the medication, the patient may not be able to fill it at any pharmacy. The plan may require a contracted specialty pharmacy.

Verify:

  • Required specialty pharmacy
  • Prescription routing
  • Enrollment
  • Patient consent when needed
  • Delivery location
  • Refill process
  • Authorization linkage
  • Copay information

Do not stop the workflow at:

PA Approved.

For specialty drugs, the next question is:

Can the approved medication actually be dispensed and delivered?

Medical-Benefit Drugs Require Coding Verification

For physician-administered medications, authorization should connect directly to medical coding.

Verify:

  • HCPCS/J-code
  • NDC when required
  • Drug name
  • Strength
  • Dose
  • Units
  • Diagnosis
  • Route
  • Frequency
  • Site of administration

You Need to Understand HCPCS Units Before Requesting Authorization

This is particularly important for J-code medications. One billing unit may represent:

  • 1 mg
  • 5 mg
  • 10 mg
  • 20 mg
  • 100 units
  • One vial
  • Another code-defined quantity

The prescribed dose therefore needs to be converted into the appropriate billing units.

Conceptually:

Prescribed Dose ÷ HCPCS Unit Definition = Units Needed

Then consider:

  • Frequency
  • Number of administrations
  • Authorization period

The authorization specialist and coding/billing team should agree on the expected units before submission.

Biosimilars Have Changed Specialty Drug Authorization

Biologics increasingly have biosimilar alternatives. FDA explains that an approved biosimilar is highly similar to its reference biologic and has no clinically meaningful differences in safety and effectiveness. This matters operationally because payers may prefer a particular biosimilar.

A PA request for a reference biologic may therefore trigger questions such as:

  • Has the preferred biosimilar been tried?
  • Is there a clinical reason it cannot be used?
  • Is the requested product preferred under the patient’s plan?
  • Is a product-specific authorization required?

Interchangeability Does Not Mean Better

This is an important clinical distinction. FDA states that both biosimilars and interchangeable biosimilars meet rigorous standards and are as safe and effective as their reference products. “Interchangeable” has a specific regulatory meaning related to pharmacy-level substitution; it does not mean the product is clinically superior to a non-interchangeable biosimilar.

Depending on state law, an interchangeable biosimilar may be substituted for its reference product at the pharmacy without contacting the prescriber. That issue should be kept separate from the payer’s formulary preference and PA requirements.

Oncology Drug Authorization Needs Disease-Specific Precision

Oncology authorization can be especially complex. The request may need information about:

  • Cancer type
  • Histology
  • Stage
  • Biomarker status
  • Mutation
  • Receptor status
  • Line of therapy
  • Previous chemotherapy
  • Previous targeted therapy
  • Previous immunotherapy
  • Disease progression
  • Combination regimen
  • Treatment cycle
  • Dose
  • Frequency
  • Performance status

Gene and Cell Therapies Require Advanced Authorization Planning

High-cost gene and cell therapies can involve some of the most complicated drug authorization workflows. The process may involve:

  • Benefit verification
  • Center-of-excellence requirements
  • Network restrictions
  • Genetic confirmation
  • Disease-specific criteria
  • Previous therapy
  • Baseline testing
  • Facility qualification
  • Case management
  • Single-case agreements
  • Financial clearance
  • Travel/logistical coordination

Renewal Authorizations Should Begin Before the Current Approval Expires

Many medications are approved only for a limited period. Continuation may require evidence that treatment is working. Possible renewal criteria include:

  • Clinical response
  • Improved laboratory values
  • Reduced symptoms
  • Disease stability
  • Functional improvement
  • Adherence
  • Absence of unacceptable toxicity
  • Continued medical necessity

Create a Drug PA Renewal Calendar

For chronic therapies, track:

FieldPurpose
MedicationIdentifies therapy
Authorization numberLinks approval
Approval dateEstablishes timeline
Expiration dateDrives renewal
Approved quantityPrevents overuse
Approved unitsMedical-benefit control
Required labsRenewal criteria
Follow-up visitClinical reassessment
Renewal start datePrevents interruption

Pharmacy Rejections Can Reveal the Real Problem in Your Authorization

Sometimes the practice does not discover the PA requirement until the pharmacy processes the prescription. The rejection may indicate:

  • PA required
  • Drug not covered
  • Refill too soon
  • Quantity limit
  • Step therapy
  • Non-network pharmacy
  • Invalid member information
  • Product not on formulary

Medicare Part D Has Its Own Drug PA Framework

For Medicare Part D, an authorization request can fall within the formal coverage determination process. CMS defines coverage determinations broadly enough to include decisions about whether a member has satisfied prior authorization, step therapy, quantity-limit, formulary, or other drug-coverage requirements.

For providers, that means Part D drug PA is connected to formal beneficiary coverage and appeal rights. The workflow can progress through:

Coverage Determination → Redetermination → Independent Review → Further Appeal Levels

Standard and Expedited Part D Requests Are Different

A prescriber or member can request a standard or expedited Part D coverage determination.

An expedited request is appropriate when applying the standard timeframe could seriously jeopardize the enrollee’s life or health or ability to regain maximum function under the applicable Medicare rules.

Do not label a request urgent simply because the office submitted it late. Clinical urgency should drive expedited review.

You Can Appeal For Part D Denials

If a Medicare Part D coverage determination is denied, the enrollee, prescriber, or representative may request a redetermination. CMS currently states that a redetermination generally must be requested within 65 calendar days of the coverage-determination notice. The plan must decide a standard redetermination within seven calendar days and an expedited redetermination within 72 hours, subject to the applicable rules. The authorization team should immediately record the appeal deadline when a denial is received.

Medicaid Drug Authorization Follows Another Legal Framework

Medicaid outpatient prescription-drug coverage has separate federal requirements. CMS guidance explains that states may subject covered outpatient drugs to prior authorization consistent with section 1927 of the Social Security Act, while Medicaid’s drug rebate framework establishes broader coverage requirements for participating manufacturers’ covered outpatient drugs, subject to statutory restrictions and exceptions. In practice, Medicaid drug PA can vary significantly by:

  • State
  • Fee-for-service program
  • Managed care plan
  • Preferred drug list
  • Drug class
  • Patient population

Commercial Drug PA Is Highly Plan-Specific

Commercial plans do not operate under one universal drug PA rulebook. Criteria can differ by:

  • Insurer
  • Employer plan
  • PBM
  • Formulary
  • State
  • Funding arrangement
  • Drug
  • Indication

That means a drug approved for Patient A under one employer plan may require completely different documentation for Patient B even when both insurance cards display the same insurer’s brand.

Build a Complete Drug PA Submission Checklist

Before submitting, verify:

CategoryRequired Review
PatientName, DOB, member ID
BenefitPharmacy or medical
Payer/PBMCorrect review entity
DrugExact product
StrengthCorrect
DoseCorrect
RouteCorrect
FrequencyCorrect
QuantityCorrect
DurationCorrect
DiagnosisDocumented
Previous therapyComplete
FailuresClearly explained
ContraindicationsSupported
LabsCurrent when required
Clinical notesRelevant
PharmacyCorrect specialty/network pharmacy
ProviderCorrect prescriber/rendering provider
FacilityCorrect administration site
CodingNDC/HCPCS/J-code when applicable

Write the Clinical Rationale Like a Reviewer Will Read It

A good authorization request answers a logical sequence:

What does the patient have?

How severe is it?

What has already been tried?

What happened?

Why are preferred alternatives inappropriate?

Why is this medication appropriate now?

A concise but complete clinical rationale is usually more useful than attaching hundreds of pages without explanation.

Common Drug PA Denial Reasons

Drug authorizations may be denied because:

Diagnosis Does Not Meet Criteria

The submitted indication does not satisfy coverage requirements.

Step Therapy Is Incomplete

Required preferred alternatives were not documented.

Treatment Failure Is Poorly Documented

The record says “failed” without explaining dose, duration, or outcome.

Drug Is Non-Formulary

A formulary exception may be needed instead.

Quantity Exceeds Limit

The requested dose or amount exceeds plan rules.

Missing Laboratory Results

Required testing was not submitted.

Wrong Benefit

The request was sent to pharmacy benefit when it belongs under medical benefit, or vice versa.

Wrong Product

The payer prefers another formulation or biosimilar.

Site-of-Care Requirement

The requested administration site does not meet policy.

Duplicate Request

Another authorization is already active.

Insufficient Clinical Information

The payer cannot complete medical-necessity review.

Peer-to-Peer Review May Be Available for Medical-Benefit Drugs

For certain medical-benefit drug denials, a payer may offer peer-to-peer review. Prepare the physician before the discussion, you need to provide:

  • Denial reason
  • Applicable policy
  • Diagnosis
  • Clinical history
  • Previous therapies
  • Treatment outcomes
  • Relevant labs
  • Imaging/pathology when applicable
  • Drug regimen
  • Dose
  • Clinical rationale

Never Promise a Patient That Approval Means Zero Cost

Authorization approval means the payer has approved the request under the applicable authorization process. It does not necessarily mean:

  • No deductible
  • No copay
  • No coinsurance
  • No specialty-pharmacy restriction
  • No benefit limit
  • Full payment

Patient financial responsibility should be verified separately.

Authorization Does Not Guarantee Medical-Claim Payment Either

For medical-benefit drugs, payment can still depend on:

  • Eligibility on DOS
  • Network status
  • Provider enrollment
  • Correct HCPCS
  • Correct units
  • NDC reporting
  • Diagnosis
  • Place of service
  • Authorized dates
  • Authorized provider
  • Authorized facility
  • Claim edits
  • Contract terms

Perform a Pre-Administration Drug Clearance

Before administering a high-cost medication, complete a final check.

Confirm:

Coverage active?

Correct benefit?

Authorization approved?

Correct drug/product?

Correct dose?

Correct units?

Correct frequency?

Correct provider?

Correct facility/site?

Authorization still valid?

Specialty pharmacy requirements completed?

Patient financial responsibility reviewed?

Use a Four-Way Match for Medical-Benefit Drugs

For provider-administered medications, a three-way claim match may not be enough.

Compare:

1. Authorization

What drug, dose, units, dates, and site were approved?

2. Medication Order

What did the physician order?

3. Administration Record

What was actually administered?

4. Claim

What is being billed?

The goal is:

Authorization = Order = Administration = Claim

Any mismatch should be investigated before billing.

Track Drug Authorization Performance

Medication authorization should be measured like any other revenue cycle function.

Useful KPIs include:

KPIWhat It Tells You
First-pass approval rateSubmission quality
Drug PA denial rateOverall performance
Step-therapy denial rateTreatment-history quality
Missing-information rateDocumentation completeness
Average turnaround timeWorkflow speed
Pending authorization rateBacklog
Expired PA rateRenewal performance
Renewal submitted on timeContinuity of therapy
Pharmacy rejection rateFront-end benefit accuracy
Medical/pharmacy misrouting rateBenefit identification quality
Specialty-pharmacy delay rateFulfillment efficiency
Drug-related claim denial rateRevenue impact
Appeal overturn rateDenial-response effectiveness

For specialty practices, measure by:

Payer + Drug Class + Drug + Denial Reason

Drug Authorization Responsibility Matrix

TaskRecommended Owner
EligibilityEligibility team
Benefit determinationPharmacy/authorization team
Formulary checkPharmacy team
PBM identificationAuthorization/pharmacy team
PA requirementAuthorization team
DiagnosisClinical team
Treatment historyClinical team
Clinical documentationClinical team
Pharmacy ePAPA/pharmacy staff
Medical-benefit PAAuthorization team
Specialty pharmacy coordinationPharmacy team
Status follow-upAuthorization team
Renewal monitoringAuthorization team
Peer-to-peer preparationClinical + PA team
AppealClinical + appeals team
HCPCS/unit validationCoding team
Claim reconciliationCoding + billing

Responsibilities vary by organization, but ownership should be explicit.

In-House vs. Outsourced Drug Prior Authorization

Drug PA can be managed internally when the organization has:

  • Experienced staff
  • Strong EHR workflows
  • Manageable medication volume
  • Reliable clinical documentation
  • Good specialty-pharmacy relationships
  • Strong follow-up controls

External authorization support may help organizations dealing with:

  • Large specialty-drug volumes
  • Multiple PBMs
  • Complex formularies
  • High denial rates
  • Staff shortages
  • Renewal backlogs
  • Multiple medical/pharmacy benefit pathways

But outsourcing cannot replace clinical involvement.

The prescribing provider still needs to supply accurate medical information and clinical rationale.

Frequently Asked Questions About Drug Prior Authorization

Why do insurance companies require prior authorization for drugs?

Health plans use prior authorization as a utilization-management mechanism to evaluate whether specified medications meet applicable coverage and clinical requirements before coverage is provided.

Is prior authorization the same as a formulary exception?

No, a standard PA generally evaluates whether applicable criteria for a drug have been met. A formulary exception asks the plan to cover a medication that is not normally covered on the formulary or, in the Part D context, can request waiver of certain utilization-management restrictions.

What is step therapy?

Step therapy generally requires a patient to try one or more preferred treatments before the plan will cover another requested medication, unless an applicable exception is approved.

What is a quantity limit?

A quantity limit restricts the amount or dose of medication the plan covers during a specified period.

What information is commonly needed for a drug PA?

The request may require diagnosis, medication, dose, route, frequency, treatment history, previous failures, contraindications, laboratory results, clinical notes, and other drug-specific information.

Are all drug authorizations handled through the pharmacy benefit?

No, many physician-administered medications are covered under the medical benefit and can have a different authorization and billing workflow.

What is an electronic prior authorization?

Electronic prior authorization allows PA information to be exchanged electronically between prescribing systems and payers/PBMs. Medicare Part D currently uses NCPDP SCRIPT standards for electronic PA transactions.

Does Medicare Part D have electronic prior authorization?

Yes, CMS requires Part D plans to support electronic PA using the applicable NCPDP SCRIPT standard. A transition to SCRIPT version 2023011 is underway, with exclusive use required beginning January 1, 2028.

Does the 2024 CMS Prior Authorization API rule apply to drugs?

The major PA API requirements finalized in CMS-0057-F apply to covered medical items and services but exclude drugs. CMS proposed separate drug-related interoperability and PA requirements in 2026.

Can a non-formulary drug still be covered?

Potentially. Depending on the plan and applicable rules, a provider or patient may be able to request a formulary exception supported by clinical justification.

Does FDA approval guarantee insurance coverage?

No, FDA approval and health-plan coverage are separate determinations.

Are biosimilars less effective than reference biologics?

FDA says approved biosimilars have no clinically meaningful differences from their reference products in safety and effectiveness.

Does interchangeable biosimilar mean it is more effective?

No, FDA explains that interchangeability relates to additional statutory requirements and potential pharmacy-level substitution; it does not mean an interchangeable biosimilar is safer or more effective than another approved biosimilar.

Can a drug authorization expire?

Yes, many authorizations have defined validity periods, quantities, doses, units, or treatment durations. Long-term therapies may require renewal.

Does drug PA approval guarantee reimbursement?

No, coverage, eligibility, coding, network, benefit, pharmacy, claim, and patient cost-sharing requirements can still apply.

Related Prior Authorization Guides

Need Expert Help With Drug Prior Authorization Rules Are More Than a Checklist: Understand What Determines Approval, Delays, and Denials?

Let our certified billing specialists handle coding, claims and denials so you can focus on patient care. Talk to our team today.